We use light to develop advanced diagnostic tools, wearable sensors, and microscale robots for studying diseases and enabling minimally invasive treatments.

Head of Group

Dr Alex Thompson

Office B411, Bessemer Building,
South Kensington Campus

⇒ X @_Thompson_Alex

 

 

What we do

We use photonics to develop new technologies for medicine and to study the pathophysiology of disease. This includes new and improved diagnostic tools as well as microscale robotic devices for therapeutic applications. We use a variety of optical techniques for this purpose such as fluorescence, Raman and diffuse reflectance spectroscopy, as well as microscopy and interferometry. We develop devices ranging from wearable sensors and fibre-optic probes for minimally invasive diagnostics through to microscale robots for cellular-scale manipulation and therapy.

Why it is important?

Our research has a number of potential clinical applications including improved monitoring of clinical therapies and interventions (e.g. in inflammatory bowel disease and malnutrition), early diagnosis of infection, and even margin mapping in tumour resection surgery.

How can it benefit patients?

The devices we are developing can potentially provide less invasive and lower cost diagnostics. In turn, this may facilitate patient benefits including earlier diagnosis, earlier identification of relapse (e.g. in therapy response monitoring applications), more widespread deployment and more comfortable patient experiences (e.g. through use of less invasive probes and sensors).

Meet the team

Dr Nilanjan Mandal

Dr Nilanjan Mandal
Research Associate in Optical Sensing for LMICs

Mr Zeyu Wang

Mr Zeyu Wang
Research Postgraduate

Citation

BibTex format

@inproceedings{McHutchison:2010:10.1016/S0168-8278(10)61182-8,
author = {McHutchison, JG and Thompson, AJ and Jacobson, IM and Boyer, TD and Schiff, ER and Everson, GT and Vierling, JM and Shiffman, ML and Brown, RS and Di, Bisceglie AM and Gordon, SC and Lee, WM and Guo, Z and King, TH and Armstrong, B and Rodell, TC and Apelian, D},
doi = {10.1016/S0168-8278(10)61182-8},
pages = {S457--S457},
publisher = {ELSEVIER SCIENCE BV},
title = {PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL <i>IL</i>-<i>28</i>B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN},
url = {http://dx.doi.org/10.1016/S0168-8278(10)61182-8},
year = {2010}
}

RIS format (EndNote, RefMan)

TY  - CPAPER
AU - McHutchison,JG
AU - Thompson,AJ
AU - Jacobson,IM
AU - Boyer,TD
AU - Schiff,ER
AU - Everson,GT
AU - Vierling,JM
AU - Shiffman,ML
AU - Brown,RS
AU - Di,Bisceglie AM
AU - Gordon,SC
AU - Lee,WM
AU - Guo,Z
AU - King,TH
AU - Armstrong,B
AU - Rodell,TC
AU - Apelian,D
DO - 10.1016/S0168-8278(10)61182-8
EP - 457
PB - ELSEVIER SCIENCE BV
PY - 2010///
SN - 0168-8278
SP - 457
TI - PHARMACOGENOMIC ANALYSIS REVEALS IMPROVED VIROLOGIC RESPONSE IN ALL <i>IL</i>-<i>28</i>B GENOTYPES IN NAIVE GENOTYPE 1 CHRONIC HCV PATIENTS TREATED WITH GI-5005 THERAPEUTIC VACCINE PLUS PEG-IFN/RIBAVIRIN
UR - http://dx.doi.org/10.1016/S0168-8278(10)61182-8
ER -

Contact Us

General enquiries

Facility enquiries


The Hamlyn Centre
Bessemer Building
South Kensington Campus
Imperial College
London, SW7 2AZ
Map location